Autoimmune Urticaria: Anti-IgE/FcεRI Antibodies & Omalizumab Response

Clinical Overview

Autoimmune urticaria (AU) is a subset of chronic spontaneous urticaria (CSU) in which circulating IgG autoantibodies against the high-affinity IgE receptor (FcεRI) or IgE itself directly activate mast cells, leading to degranulation and histamine release. Approximately 30-40% of CSU patients have autoimmune pathophysiology. This distinction is clinically important because autoimmune urticaria typically responds well to omalizumab, a recombinant anti-IgE monoclonal antibody, whereas some other CSU phenotypes may have different response patterns to advanced therapies.

Epidemiology & Risk Factors

Autoimmune urticaria accounts for 30-40% of CSU cases. It is more common in females and often presents in the fourth to sixth decade of life. Key associations include:

• Other autoimmune diseases: Thyroid disease (20-25% of AU patients have elevated TPO antibodies), systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome
• Elevated inflammatory markers: ESR and CRP may be elevated in some AU patients
• Detection of anti-FcεRI or anti-IgE antibodies: The defining feature, detectable in 30-40% of CSU patients

Pathophysiology

In autoimmune urticaria, IgG autoantibodies bind to epitopes on the alpha chain of FcεRI or to the constant region of IgE, crosslinking these receptors and activating mast cells directly, independent of allergen exposure. This explains the "spontaneous" and persistent nature of autoimmune CSU.

Mechanism of mast cell activation: Crosslinking of FcεRI by anti-FcεRI antibodies or crosslinking of IgE-bound receptors by anti-IgE antibodies triggers the same downstream signaling cascades as allergen-induced activation, resulting in degranulation and release of histamine, tryptase, IL-6, TNF-α, and other mediators.

Why omalizumab is effective: Omalizumab, a monoclonal antibody against the Cε3 domain of IgE, binds circulating IgE and prevents its interaction with FcεRI. In AU, this reduces IgE-mediated cross-linking and lessens mast cell activation, even though the autoantibodies persist.

Clinical Presentation & Classification

Autoimmune urticaria presents identically to other forms of CSU: recurrent urticarial wheals and/or angioedema on ≥4 days per week for ≥6 weeks. The clinical presentation does not distinguish autoimmune from other CSU phenotypes; diagnosis requires serologic testing. Autoimmune CSU may have slightly higher disease activity and disease severity compared to non-autoimmune CSU in some studies, though there is significant overlap.

Autoimmune urticaria may be associated with systemic symptoms such as malaise, low-grade fever, or arthralgias, particularly if concurrent autoimmune thyroid disease is present.

Diagnosis & Workup

Clinical diagnosis: Chronic spontaneous urticaria with features suggesting autoimmune pathophysiology:

• Persistent or exacerbating disease despite high-dose antihistamines
• Associated autoimmune diseases or positive autoimmune markers
• Female predominance, middle-aged patient

Serologic confirmation (optional but helpful):

• Autologous serum skin test (ASST): Intradermal injection of patient's own serum produces wheal >1.5 mm larger than saline control in 30-40% of CSU patients (positive in autoimmune AU). Non-invasive version (whole blood) available. Positive ASST suggests autoimmune pathophysiology but is not specific—can be positive in other CSU phenotypes.
• Basophil activation test (BAT): Flow cytometry-based test measuring upregulation of CD63 and CD203c on basophils exposed to patient serum. Detects circulating factors (IgG autoantibodies) that activate basophils. More specific and sensitive than ASST for autoimmune urticaria. Available at specialized immunology laboratories.
• Direct detection of autoantibodies: Anti-FcεRI antibody testing and anti-IgE antibody testing available at research centers. Not routinely performed in clinical practice but confirm autoimmune pathophysiology when positive.

Screening for associated conditions:

• TSH and TPO antibodies (thyroid disease)
• Antinuclear antibody (ANA), anti-dsDNA, and complement levels (if suspicion for SLE)
• Complete blood count (evaluate for cytopenias)

Important: Absence of positive autoimmune serology does not exclude autoimmune CSU, nor does a positive ASST or BAT diagnostic by itself—clinical context is required.

Treatment Algorithm

First-Line: High-Dose H1 Antihistamines

Begin with second-generation H1-antihistamines at standard doses (cetirizine 10 mg, desloratadine 5 mg, fexofenadine 180 mg daily). If inadequate response at 4 weeks, escalate to up to 4-fold standard dose (cetirizine 40 mg daily, desloratadine 20 mg daily). Approximately 40-50% of autoimmune CSU patients achieve control on high-dose antihistamines.

Second-Line: Omalizumab

For patients inadequately controlled on high-dose antihistamines, add omalizumab 150-375 mg subcutaneously every 4 weeks (dose based on baseline IgE and weight). Omalizumab is particularly effective in autoimmune CSU: the ASTERIA II trial (pivotal trial in CSU) enrolled patients with both IgE-mediated and autoimmune CSU and demonstrated:

• ASST 50 (≥50% reduction in wheal count on repeat ASST) achieved in 67% of omalizumab vs 5% placebo
• Pruritus-free days (0 on activity-free days) achieved in 33% omalizumab vs 2% placebo
• Minimal side effect difference between omalizumab and placebo

Full efficacy typically achieved by 12-16 weeks. Continue omalizumab while symptoms are controlled; taper or discontinue if sustained remission occurs, though relapse upon discontinuation occurs in some patients.

Third-Line: Cyclosporine or JAK Inhibitors

For omalizumab failures:

• Cyclosporine: 1-5 mg/kg/day in divided doses. Response rates 60-80% in small case series. Requires monitoring renal function and blood pressure every 2-4 weeks. Dose and trough levels based on clinical response; typical therapeutic range 75-150 ng/mL. Limit long-term use due to nephrotoxicity.
• JAK inhibitors: Baricitinib 2-4 mg daily emerging as alternative; clinical trial data in CSU ongoing. Initial studies show good efficacy and improved tolerability compared to cyclosporine.

Adjunctive Therapies

Management of concurrent autoimmune thyroid disease: Treat hypothyroidism with levothyroxine; target TSH in normal range. This may improve urticaria control.

Avoid triggers: NSAIDs and ACE inhibitors may exacerbate CSU and should be avoided if possible. Alternative analgesics (acetaminophen) and antihypertensive classes preferred.

Prognosis & Complications

Autoimmune urticaria has a variable prognosis. Spontaneous remission rates are 20-30% annually, similar to non-autoimmune CSU. Disease control is excellent with modern therapies (omalizumab achieves control in 60-80% of previously refractory patients). Major complications include airway angioedema (rare but life-threatening) and psychological impact of chronic disease.

When to See a Dermatologist

Referral to dermatology is indicated for:

• Initial diagnosis and confirmation of CSU
• Suspected autoimmune urticaria (persistent disease despite high-dose antihistamines)
• Initiation and monitoring of omalizumab or advanced therapies
• Evaluation for associated autoimmune conditions
• Disease management optimization and specialist-level care

Frequently Asked Questions

What does "autoimmune urticaria" mean, and how is it different from regular urticaria?

In typical urticaria, the body reacts to specific triggers (allergens, stress, temperature). In autoimmune urticaria, the immune system mistakenly produces antibodies against the body's own mast cells or the IgE that binds to them. These autoantibodies continuously activate mast cells to release histamine without any external trigger—the urticaria is truly spontaneous. Approximately 30-40% of patients with chronic spontaneous urticaria have this autoimmune form. The distinction is important because autoimmune urticaria typically responds very well to a specific medication called omalizumab, which reduces IgE levels and prevents the autoantibodies from triggering mast cells. Determining whether you have autoimmune urticaria requires specific blood tests or skin tests (like the autologous serum skin test).

Can a simple blood test tell me if I have autoimmune urticaria?

Not yet in most clinical settings. Direct testing for the autoantibodies responsible for autoimmune urticaria (anti-FcεRI and anti-IgE antibodies) is available only at specialized research laboratories, not routine clinical labs. However, two tests can support the diagnosis: the autologous serum skin test (ASST), in which a small amount of your own blood serum is injected under the skin to see if it triggers a wheal reaction (suggesting autoimmune activity), and the basophil activation test (BAT), a specialized blood test measuring whether your serum activates white blood cells (basophils) in a test tube. A positive result in either test suggests autoimmune pathophysiology. However, diagnosis does not require these tests—your clinical response to treatment and other features can also indicate autoimmune disease.

If I have autoimmune urticaria, will omalizumab cure it?

Omalizumab is highly effective at controlling the symptoms of autoimmune urticaria—achieving complete control in about 30-35% of patients and significant improvement in another 30-40%. However, omalizumab does not eliminate the autoantibodies themselves; it works by reducing IgE levels and preventing mast cell activation. Most patients require ongoing omalizumab therapy to maintain control; if the medication is discontinued, urticaria typically recurs within weeks. That said, some patients achieve long-term remission and can eventually discontinue the medication under medical supervision. The goal is to achieve symptom control and improve your quality of life, which omalizumab accomplishes in the majority of autoimmune urticaria patients who don't respond to standard antihistamines.

Should I take immunosuppressive medications for autoimmune urticaria?

Most autoimmune urticaria is effectively treated with antihistamines and omalizumab without need for systemic immunosuppression. Cyclosporine (an immunosuppressive drug) is reserved for patients who fail omalizumab and requires close monitoring of kidney function and blood pressure. JAK inhibitors (newer agents that modulate immune signaling) are emerging as a potentially better-tolerated alternative to cyclosporine for refractory cases. The decision to use immunosuppressive therapy should be made with a dermatologist or immunologist after discussing the severity of your disease, impact on quality of life, and risks versus benefits of each treatment option.

References